These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35934766)

  • 1. IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.
    Avsar T; Kose TB; Oksal MD; Turan G; Kilic T
    Mol Biol Rep; 2022 Oct; 49(10):9241-9249. PubMed ID: 35934766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
    Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
    Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87‑MG cells.
    Gao Y; Wu Y; Zhang N; Yuan H; Wang F; Xu H; Yu J; Ma J; Hou S; Cao X
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
    Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
    Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
    Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
    Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
    Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
    Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
    Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A
    Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
    Mohamed E; Kumar A; Zhang Y; Wang AS; Chen K; Lim Y; Shai A; Taylor JW; Clarke J; Hilz S; Berger MS; Solomon DA; Costello JF; Molinaro AM; Phillips JJ
    Neuro Oncol; 2022 Sep; 24(9):1471-1481. PubMed ID: 35287169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
    Doll S; Urisman A; Oses-Prieto JA; Arnott D; Burlingame AL
    Mol Cell Proteomics; 2017 Jan; 16(1):39-56. PubMed ID: 27834733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
    Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
    Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.
    Wang G; Sai K; Gong F; Yang Q; Chen F; Lin J
    Mol Med Rep; 2014 May; 9(5):1799-805. PubMed ID: 24626950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
    Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
    Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 mutation promotes proliferation and migration of glioma cells via EMT induction.
    Lu J; Li D; Zeng Y; Wang H; Feng W; Qi S; Yu L
    J BUON; 2019; 24(6):2458-2464. PubMed ID: 31983120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation.
    Zhu J; Cui G; Chen M; Xu Q; Wang X; Zhou D; Lv S; Fu L; Wang Z; Zuo J
    J Mol Neurosci; 2013 May; 50(1):165-71. PubMed ID: 23011765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
    Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
    PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The atypical protein kinase RIOK3 contributes to glioma cell proliferation/survival, migration/invasion and the AKT/mTOR signaling pathway.
    Zhang T; Ji D; Wang P; Liang D; Jin L; Shi H; Liu X; Meng Q; Yu R; Gao S
    Cancer Lett; 2018 Feb; 415():151-163. PubMed ID: 29233656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.